Ozempic Gastroparesis Settlement: Criteria Explained

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Specific Pharmaceutical Risks

For decades, public health communication has centered on general wellness and the broad dissemination of scientific knowledge. This legacy framework prioritized accessible information about nutrition, disease prevention, and the importance of routine medical oversight. Audiences were encouraged to understand their bodies through a lens of universal health principles, often without deep scrutiny of specific pharmaceutical interventions or their long-term consequences. This foundational approach served to build a baseline of health literacy across diverse populations. As medical science advanced, the conversation naturally expanded to include the nuanced effects of targeted therapies. The widespread use of medications like Ozempic, initially developed for metabolic conditions, introduced a new dimension to patient awareness. Individuals who once sought general health guidance now find themselves navigating specific exposure scenarios. The transition from broad health education to focused inquiry about drug-related risks marks a critical shift. This pivot requires examining how a patient’s history of general health management intersects with their potential exposure to GLP-1 receptor agonists. The emerging concern centers on understanding the criteria that define adverse outcomes, moving from abstract wellness to concrete, case-specific evaluation of pharmaceutical impact.

Understanding Gastroparesis and Its Link to Ozempic

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, where retention of a solid meal is measured at specified intervals. The condition can significantly impair quality of life and nutritional status. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events in those with established cardiovascular disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). GLP-1 receptor agonists slow gastric emptying as part of their mechanism of action, which can contribute to gastrointestinal adverse effects. Clinical trial data show that gastrointestinal adverse reactions occur more frequently among patients receiving Ozempic than placebo. In pooled placebo-controlled trials, gastrointestinal adverse reactions were reported in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% of those on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions occurred in 3.1% of patients on Ozempic 0.5 mg and 3.8% on Ozempic 1 mg, compared to 0.4% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with the 2 mg dose (34.0%) versus the 1 mg dose (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% associated with Ozempic include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed in these trial data, the reported symptoms—particularly nausea, vomiting, dyspepsia, and gastroesophageal reflux—overlap with the clinical presentation of gastroparesis. The mechanistic pathway linking Ozempic to gastroparesis involves GLP-1 receptor agonist-induced delay in gastric emptying, which can become clinically significant in susceptible individuals, potentially leading to symptomatic gastroparesis.

Settlement Criteria and Evidence Considerations

Regarding the adequacy of warnings, the prescribing information for Ozempic includes gastrointestinal adverse reactions as a known class effect, but does not specifically warn about gastroparesis as a distinct adverse event. The label notes that gastrointestinal adverse reactions occur more frequently with Ozempic than placebo and that discontinuation rates due to these reactions are higher (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific warning for gastroparesis may be relevant for settlement considerations, as patients who developed gastroparesis after Ozempic use might argue that the risk was not adequately communicated. Settlement-related considerations for affected patients typically involve documenting a clear timeline between Ozempic exposure and the onset of gastroparesis symptoms. Evidence of temporal association—such as symptom onset during dose escalation or shortly after initiating treatment—strengthens a potential claim. Patients should also have a confirmed diagnosis of gastroparesis via objective testing, such as gastric emptying scintigraphy, and medical records showing that other causes (e.g., diabetes-related autonomic neuropathy, prior surgery, or idiopathic factors) were reasonably excluded. The severity and duration of harm, including hospitalizations, nutritional interventions, or disability, may influence settlement value. The timeline between exposure and documented harm is critical. In clinical trials, gastrointestinal adverse reactions occurred predominantly during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), suggesting that early symptoms may be a warning sign. However, some patients may develop gastroparesis after prolonged use, and the latency period can vary. Medical records should capture the date of first Ozempic prescription, dose changes, and the date of gastroparesis diagnosis to establish a plausible causal relationship. In summary, while Ozempic is effective for glycemic control and cardiovascular risk reduction, its gastrointestinal adverse effects—including those overlapping with gastroparesis—are well-documented in clinical trials. The lack of a specific gastroparesis warning in the label may be a point of contention in settlement discussions. Affected patients should seek legal counsel to evaluate their individual circumstances, including the strength of the temporal link and the adequacy of warnings provided by the manufacturer.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. This can lead to gastrointestinal symptoms such as nausea, vomiting, and dyspepsia, which overlap with gastroparesis. While not explicitly listed as a side effect, clinical trials show higher rates of these symptoms in Ozempic users compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What evidence is needed for an Ozempic gastroparesis settlement claim?

Key evidence includes a confirmed gastroparesis diagnosis via gastric emptying scintigraphy, a clear timeline of Ozempic exposure and symptom onset, medical records excluding other causes, and documentation of harm severity such as hospitalizations or nutritional interventions. The absence of a specific gastroparesis warning in the label may strengthen claims (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.